Back to Browse Journals » Drug Design, Development and Therapy » Volume 3

Troglitazone reverses the multiple drug resistance phenotype in cancer cells

Authors Gerald F Davies, Bernhard HJ Juurlink, Troy AA Harkness

Published Date March 2009 Volume 2009:3 Pages 79—88

DOI http://dx.doi.org/10.2147/DDDT.S3314

Published 17 March 2009

Gerald F Davies1, Bernhard HJ Juurlink2, Troy AA Harkness1

1Department of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Saskatoon, Canada; 2College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia

Abstract: A major problem in treating cancer is the development of drug resistance. We previously demonstrated doxorubicin (DOX) resistance in K562 human leukemia cells that was associated with upregulation of glyoxalase 1 (GLO-1) and histone H3 expression. The thiazolidinedione troglitazone (TRG) downregulated GLO-1 expression and further upregulated histone H3 expression and post-translational modifications in these cells, leading to a regained sensitivity to DOX. Given the pleiotropic effects of epigenetic changes in cancer development, we hypothesized that TRG may downregulate the multiple drug resistance (MDR) phenotype in a variety of cancer cells. To test this, MCF7 human breast cancer cells and K562 cells were cultured in the presence of low-dose DOX to establish DOX-resistant cell lines (K562/DOX and MCF7/DOX). The MDR phenotype was confirmed by Western blot analysis of the 170 kDa P-glycoprotein (Pgp) drug efflux pump multiple drug resistance protein 1 (MDR-1), and the breast cancer resistance protein (BCRP). TRG markedly decreased expression of both MDR-1 and BCRP in these cells, resulting in sensitivity to DOX. Silencing of MDR-1 expression also sensitized MCF7/DOX cells to DOX. Use of the specific and irreversible peroxisome proliferator-activated receptor gamma (PPARγ) inhibitor GW9662 in the nanomolar range not only demonstrated that the action of TRG on MCF/DOX was PPARγ-independent, but indicated that PPARγ may play a role in the MDR phenotype, which is antagonized by TRG. We conclude that TRG is potentially a useful adjunct therapy in chemoresistant cancers.

Keywords: chemotherapy, doxorubicin, breast cancer resistance protein-1, multiple drug resistance, multiple drug resistance protein 1

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Multifunctional materials for bone cancer treatment

Marques C, Ferreira JMF, Andronescu E, Ficai D, Sonmez M, Ficai A

International Journal of Nanomedicine 2014, 9:2713-2725

Published Date: 28 May 2014

In vivo and in vitro evaluation of octyl methoxycinnamate liposomes

de Carvalho Varjão Mota A, Freitas ZMF, Ricci Júnior E, Dellamora-Ortiz GM, Santos-Oliveira R, Ozzetti RA, Vergnanini AL, Lira Ribeiro V, Silva RS, Santos EP

International Journal of Nanomedicine 2013, 8:4689-4701

Published Date: 10 December 2013

Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin

Zhang KC, Lv SW, Li XY, Feng YF, Li X, Liu L, Li S, Li YJ

International Journal of Nanomedicine 2013, 8:3227-3239

Published Date: 22 August 2013

Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex

Zhang J, Peng Q, Shi S, Zhang Q, Sun X, Gong T, Zhang Z

International Journal of Nanomedicine 2011, 6:3405-3414

Published Date: 19 December 2011

Molecular network topology and reliability for multipurpose diagnosis

Jalil MA, Moongfangklang N, Innate K, Mitatha S, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:2385-2392

Published Date: 19 October 2011

Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy

Tommaso Iannitti, Stefania Capone, Antonietta Gatti, et al

International Journal of Nanomedicine 2010, 5:955-960

Published Date: 15 November 2010

Thermosensitive Pluronic® hydrogel: prolonged injectable formulation for drug abuse

Katayoun Derakhshandeh, Mahtab Fashi, Seyedalireza Seifoleslami

Drug Design, Development and Therapy 2010, 4:255-262

Published Date: 20 September 2010